Question

Atezolizumab, an ɑ-PD-L1 monoclonal antibody, was recently approved for use in triple negative breast cancer in cases where multiple lines of chemotherapy have failed and PD-L1 is expressed.

Which of the following terms describe atezolizumab? (Select two answers.)

immune checkpoint inhibitor

passive immunotherapy

active immunotherapy

ɑ-receptor antibody

Answer 1

Immune checkpoint inhibitor.

Passive immunotherapy.

Atezolizumab is an Immune checkpoint inhibitor which stops binding of PD-1 to PD-L1 . This helps in T cells to fight breast cancer cells. PD-1 and PD-L1 are immune  checkpoint proteins.

Passive immunotherapy is the one that uses the method of provoking immune response by using immune checkpoint inhibitors, antibodies etc. Atezolizumab is used in passive immunotherapy.

Active immunotherapy is in which the body is provided with the necessary components for the productions of antibodies on its own.

Atezolizumab is not an alpha receptor antibody.